Loading...
Frontpage2024-03-19T09:06:39+01:00

The aim of the EuroSpA Research Collaboration Network

The aim of the EuroSpA Research Collaboration Network (RCN) is to jointly address research questions in SpA including, but not limited to, real world effectiveness and safety profiles of biologic therapies. This is done by retrospectively and prospectively collecting real life patient data from European registers.

The collaboration promotes opportunities to identify unmet needs in the treatment of SpA patients by utilizing high-quality data from existing patient registries.

Our aims are in line with the EMA initiative for patient registries and are consistent with discussions at the EMA workshop “How to make better use of patient registries to collect high-quality data on medicines” held in London on October 28th, 2016 in London.

EuroSpA RCN Scope

Currently the collaboration consists of 17 registries (see map).

There is a recognized openness to include other interested registries and to other parties such as health authorities (EMA and local regulatory bodies) and patient organizations, although the extent of their involvement will need to be further defined.

Acknowledgements

Novartis Pharma AG for supporting the EuroSpA collaboration.
UCB Biopharma SRL for supporting the EuroSpA collaboration.

Registries that contribute data to the collaboration

ARC (Netherlands)

ATTRA (Czech Republic)

BIOBADASER (Spain)

Biorx.si (Slovenia)

BSRBR-AS (United Kingdom)

DANBIO (Denmark)

ESTONIA (ERS Biologic Therapy Register)

GISEA (Italy)

ICEBIO (Iceland)

NOR-DMARD (Norway)

RABBIT-SpA (Germany)

Reuma.pt (Portugal)

ROBFIN (Finland)

Romanian registry of Rheumatic Diseases

SCQM (Switzerland)

SRQ (Sweden)

TURKBIO (Turkey)

The most recent EuroSpA publications

EuroSpA publication 4.2

By |November 6th, 2023|Categories: News|

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration Click here to access full [...]

Comments Off on EuroSpA publication 4.2

EuroSpA publication 1A

By |November 6th, 2023|Categories: News|

European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response Click here to access full article [...]

Comments Off on EuroSpA publication 1A

EuroSpA publication 3.2

By |November 6th, 2023|Categories: News|

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis Click here [...]

Comments Off on EuroSpA publication 3.2

EuroSpA publication 6.1

By |November 6th, 2023|Categories: News|

Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries [...]

Comments Off on EuroSpA publication 6.1

EuroSpA publication 6.2

By |November 6th, 2023|Categories: News|

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the [...]

Comments Off on EuroSpA publication 6.2

To see full list, please click Publications in top menu

EuroSpA meetings

EuroSpA Scientific Committee consists of representatives from the 17 participating registries, who meets for hybrid meetings twice yearly in Copenhagen and online.

Go to Top